Advertisement
News
Advertisement

Advantages of OptiMedica’s Catalys® Precision Laser System to Be Validated in 31 Clinical Presentations at ASCRS 2013

Wed, 04/17/2013 - 7:00am
The Associated Press

SUNNYVALE, Calif.--(BUSINESS WIRE)--Apr 17, 2013--OptiMedica Corp. has announced that its Catalys Precision Laser System will be the subject of 31 accepted clinical presentations at the 2013 American Society of Cataract and Refractive Surgery (ASCRS) conference, April 19 - 23, in San Francisco. The presentations, which will include posters, courses, videos and free papers, are expected to further substantiate Catalys’ unmatched performance and clinical results in the field of laser cataract surgery. The news comes just three years after OptiMedica unveiled its laser cataract surgery program at ASCRS 2010.

At this year’s meeting, ASCRS attendees will learn from an international roster of cataract experts with extensive experience using Catalys in clinical practice. The presenters will explore several system-specific advantages, including: Broad inclusion criteria, even encompassing patients with glaucoma; Demonstrated benefit in challenging cases; Significant surgical advantages, such as near or complete elimination of ultrasound energy and improved intraocular lens (IOL) positioning and centering; Short learning curve; and, Positive impact on post-operative outcomes. “We committed from OptiMedica’s founding in 2004 to make Catalys a platform that delivers the highest levels of precision and performance in laser cataract surgery. Today, cataract surgeons from around the world are indicating that we have achieved our goal,” said Mark J. Forchette, president and chief executive officer of OptiMedica. “The level of interest and responsiveness we have seen from the surgical community – both in the ways they are using Catalys, as well as their interest in conducting studies to explore its advantages – is immensely gratifying. Together, we are transforming the practice of cataract surgery for the benefit of patients across the world.” William Culbertson, MD, is the Professor of Ophthalmology, The Lou Higgins Distinguished Chair in Ophthalmology at Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami; the chair of OptiMedica’s medical advisory board; and one of a rapidly growing number of Catalys users in 12 countries around the world. At ASCRS, he will be reporting on the Catalys system’s ability to perform precise intrastromal and anterior penetrating arcuate incisions during the laser cataract procedure.

“Catalys was built from day one specifically for cataract surgery, and it makes the procedure both ultra-precise and very intuitive for both surgeons and technicians,” Dr. Culbertson said. “Having been part of the product’s development with OptiMedica, I can speak first hand to how the team tirelessly iterated to develop a system that was dependable, safe, and comfortably usable even by someone not familiar with femtosecond lasers. The system simply performs beautifully.” The ASCRS 2013 presentations are part of a growing body of peer-reviewed literature demonstrating the key benefits that Catalys brings to laser cataract surgery. A full schedule of all 31 ASCRS presentations can be found at www.optimedica.com/ASCRS2013presentations.

About Catalys
Catalys is a precision laser cataract surgery platform that delivers gentle, highly customized procedures with best-in-class accuracy and performance1-3. Catalys is the only laser platform designed specifically for laser cataract surgery, and it offers several unique benefits for surgeons and patients, including: complete capsulotomies and precision within 30 μm 1,2; lens fragmentation that segments and softens the cataract, enabling near elimination of ultrasound energy in cataracts of all grades 4,5; and, custom corneal incision architecture based on anatomical landmarks. Key proprietary features of the system include a Liquid Optics™ Interface that ensures gentle docking with minimal intraocular pressure rise and clear optics for unsurpassed imaging and laser delivery; and Integral Guidance™, 3D Full Volume Optical Coherence Tomography (OCT) and automated surface mapping algorithms that guide laser delivery. Since its international launch, Catalys has been named one of the top medical technology products in the world. In 2012, the system won the prestigious R&D 100 award from R&D Magazine and was also a finalist in the Medical Design Excellence Awards.

About OptiMedica
Founded in 2004 and headquartered in Sunnyvale, Calif., OptiMedica Corp. is a Silicon Valley-based global ophthalmic device company dedicated to developing performance-driven technologies that improve patient outcomes. Exclusively focused in the cataract therapeutic area, the company has developed the Catalys Precision Laser System to transform existing standards of care in cataract surgery. OptiMedica’s legacy of innovation in ophthalmology also includes the development and commercialization of the PASCAL® Method of retinal photocoagulation, which was acquired by Topcon Corp. in August 2010. The company is funded by Kleiner Perkins Caufield & Byers, Alloy Ventures, DAG Ventures, BlackRock Private Equity Partners and Bio*One Capital. For more information, please visit www.optimedica.com.

References
1 Palanker DV, et al. “Femtosecond laser-assisted cataract surgery with integrated optical coherence tomography.” Sci Transl Med. 2010 Nov 17;2(58):58ra85.
2  Friedman NJ, et al. “Femtosecond laser capsulotomy.” J Cataract Refract Surg. 2011 Jul;37(7):1189-98.
3  Culbertson, B. “Optimization of corneal incision parameters with a femtosecond laser for cataract surgery.” XXX Congress of the ESCRS, Sept. 2012.
4  Conrad-Hengerer I, Hengerer FH, Schultz T, Dick HB. “Effect of femtosecond laser fragmentation on effective phacoemulsification time in cataract surgery.” J Refract Surg. 2012 Dec;28(12):879-83.
5  Conrad-Hengerer I, Hengerer FH, Schultz T, Dick HB. “Effect of femtosecond laser fragmentation of the nucleus with different softening grid sizes on effective phaco time in cataract surgery.” J Cataract Refract Surg. 2012 Nov; 38(11): 1888-94.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading